Experimental triple therapy takes on Hard-to-Treat Head-Neck cancer
NCT ID NCT05838729
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new drug called RiMO-301, given as an injection directly into the tumor, along with radiation therapy and an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination is safe and can shrink tumors in people with advanced head-neck cancer that cannot be removed by surgery. The study plans to enroll 16 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RiMO-301 (a drug injected into the tumor) combined with radiation therapy and a PD-1 inhibitor (pembrolizumab or nivolumab)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced head-neck cancer that has not responded to other therapies.
What could go wrong
This is a very early, small trial with only 16 participants, so results may not apply to everyone. The combination therapy may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••